| |SEPTEMBER 20269PSYCHEDELIC DRUG SHOWS POTENTIAL BEYOND MENTAL HEALTH16.9 MILLION BY 2036: WHY INDIA NEEDS A DEMENTIA CARE ECOSYSTEM NOWNOVARTIS MS PILL: HOW DOES RHAPSIDO AVOID LIVER TOXICITY?AS SWINE FLU CASES CLIMB, UP MAKES GOVT HOSPITAL TESTING FREEIONIS WINS FDA APPROVAL FOR FIRST ALEXANDER DISEASE TREATMENTMEDICINE OVERPRICING IN INDIA: WHY COMPANIES REJECT NPPA'S PROPOSALA psychedelic drug may find a new role beyond mental health as researchers explore whether psilocybin can prevent nerve damage caused by chemotherapy.Scientists at the University of Texas MD Anderson Cancer Center found that the compound protected sensory nerves and preserved touch sensation in mice exposed to chemotherapy. POIndia faces a sharp rise in dementia that could leave 16.9 million seniors living with the condition by 2036. Tata Trusts warns that the country must move beyond early detection and build a stronger, more collaborative dementia care ecosystem now.As the population ages, the gap between need and available services will widen unless healthcare providers, families, communities and policymakers act together. POThe Novartis MS Pill, Rhapsido (remibrutinib), has cleared a major Phase 3 hurdle in relapsing multiple sclerosis (RMS). But the headline comes with an important clinical caveat.The Novartis MS pill significantly reduced annualized relapse rates (ARR) and MRI brain lesions compared with Sanofi's Aubagio (teriflunomide). POSwine flu cases climb across Uttar Pradesh as the state moves to make government hospital testing free.Chief Minister Yogi Adityanath directs free Influenza-A (H1N1) testing at every government health facility and orders stronger surveillance in districts that report higher numbers. POIonis wins FDA approval for the first Alexander disease treatment, delivering a landmark option for a rare genetic brain disorder that until now had none.The U.S. Food and Drug Administration has cleared Ionis Pharmaceuticals' injectable therapy zilganersen, branded Zanvastro, for adults and pediatric patients. POMedicine overpricing in India has triggered a sharp clash between drug makers and the pricing regulator.Companies reject the National Pharmaceutical Pricing Authority's proposal that would place sole legal responsibility for overpricing on manufacturers while shielding retail chemists, hospitals and nursing homes. PO
< Page 8 | Page 10 >